Experienced in Sarcoidosis

Dr. Thomas W. O'brien

Pulmonary Medicine | Intensive Care Medicine
1121 N Central Ave, Suite B, 
Kissimmee, FL 
Accepting New Patients
Experienced in Sarcoidosis
1121 N Central Ave, Suite B, 
Kissimmee, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Thomas O'brien is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Kissimmee, Florida. Dr. O'brien is rated as an Experienced provider by MediFind in the treatment of Sarcoidosis. His top areas of expertise are Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, and Excessive Daytime Sleepiness. Dr. O'brien is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Sarcoidosis.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Critical Care Medicine in FL
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

1121 N Central Ave, Suite B, Kissimmee, FL 34741

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR
Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR
Enrollment Status: Completed
Publish Date: October 02, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Device, Drug
Study Drug: Treprostinil
Study Phase: Phase 3
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: SUVN-G3031
Study Phase: Phase 2
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: December 17, 2024
Intervention Type: Drug, Biological
Study Drug: GSK3511294
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Belumosudil in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Belumosudil in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Completed
Publish Date: September 08, 2022
Intervention Type: Other, Drug
Study Drug: KD025
Study Phase: Phase 2
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Drug, Device
Study Phase: Phase 4
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
View 9 Less Clinical Trials

1 Total Publications

Lamin AC Cardiomyopathy, the Next Masquerader: Laminopathy Mimicking Cardiac Sarcoidosis.
Lamin AC Cardiomyopathy, the Next Masquerader: Laminopathy Mimicking Cardiac Sarcoidosis.
Journal: Cureus
Published: March 14, 2025
Similar Doctors
Advanced in Sarcoidosis
Dr. Mark Vollenweider
Intensive Care Medicine
Advanced in Sarcoidosis
Dr. Mark Vollenweider
Intensive Care Medicine

Scripts Pharmacy

1222 S Orange Ave, 
Orlando, FL 
 (15.6 miles away)
321-841-7856
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Vollenweider is an Intensive Care Medicine provider in Orlando, Florida. Dr. Vollenweider is rated as a Distinguished provider by MediFind in the treatment of Sarcoidosis. His top areas of expertise are Lung Nodules, Acquired Tracheomalacia, Tracheobronchomalacia, Advanced Bronchoscopy, and Gastrostomy.

Advanced in Sarcoidosis
Dr. Yasmeen S. Gowani
Pulmonary Medicine
Advanced in Sarcoidosis
Dr. Yasmeen S. Gowani
Pulmonary Medicine

Gowani Medical Associates Mdpllc

7224 Stonerock Cir, 
Orlando, FL 
 (9.7 miles away)
407-345-4999
Languages Spoken:
English, Hindi, Punjabi, Sindhi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Yasmeen Gowani is a Pulmonary Medicine provider in Orlando, Florida. Dr. Gowani is rated as an Advanced provider by MediFind in the treatment of Sarcoidosis. Her top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Obstructive Sleep Apnea, Cerebral Hypoxia, and Advanced Bronchoscopy. Dr. Gowani is currently accepting new patients.

Advanced in Sarcoidosis
Dr. Ivan F. Ackerman
Pulmonary Medicine | Sleep Medicine
Advanced in Sarcoidosis
Dr. Ivan F. Ackerman
Pulmonary Medicine | Sleep Medicine

Tampa Bay Pulmonary Medicine, PA

402 Noland Dr, 
Brandon, FL 
 (59.5 miles away)
813-655-2500
Languages Spoken:
English, French, Latin, Spanish
See accepted insurances
Accepting New Patients

Ivan Ackerman is a Pulmonary Medicine specialist and a Sleep Medicine provider in Brandon, Florida. Dr. Ackerman is rated as a Distinguished provider by MediFind in the treatment of Sarcoidosis. His top areas of expertise are Lung Nodules, Lung Metastases, Drowsiness, and Excessive Daytime Sleepiness. Dr. Ackerman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. O'brien's expertise for a condition
ConditionClose
      View All 24 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile